Skip to main content

Saturn Medic

Clinical Subject Page

Bladder Cancer

Bladder Cancer is a malignant tumor arising from the tissues of the urinary bladder. Most cases are urothelial carcinoma, which develops from the urothelial lining of the bladder. Bladder Cancer ranges from superficial non-muscle-invasive disease to aggressive muscle-invasive and metastatic disease

Also called

Bladder carcinoma

ICD-10

C67

Specialty

Urology

Onset

Chronic

Reviewed

August 2026
On This Page

Overview

-MostBladder Cancer is urothelial carcinoma. Clinically, it is broadly classified into:

  • Non-muscle-invasive Bladder Cancer (NMIBC): confined to the mucosa or lamina propria.

 

  • Muscle-invasive Bladder Cancer (MIBC): invades the detrusor muscle or beyond.

 

  • Metastatic Bladder Cancer: spreads to distant organs.

 

This classification is important because treatment and prognosis differ substantially between stages.

Etiology & Risk Factors

-Etiology

–Bladder Cancer develops through genetic and molecular changes in urothelial cells, often following prolonged exposure to urinary carcinogens.

Most tumors are urothelial carcinomas.

 

-Risk Factors

  • Cigarette smoking
  • Occupational exposure to aromatic amines and certain industrial chemicals
  • Increasing age
  • Chronic bladder irritation or inflammation
  • Previous pelvic radiotherapy

Pathophysiology

Exposure to urinary carcinogens → urothelial DNA damage → accumulation of genetic mutations → uncontrolled urothelial cell proliferation → tumor formation → local invasion → lymphatic and hematogenous spread in advanced disease

Clinical Presentation

-Symptoms:

  • Painless visible hematuria
  • Microscopic hematuria
  • Dysuria
  • Urinary frequency
  • Urinary urgency
  • Pelvic pain in advanced disease
  • Flank pain due to ureteric obstruction

 

-Signs:

  • Early Bladder Cancer may have no specific physical signs.

    Possible findings in advanced disease include:

    • Palpable pelvic mass
    • Weight loss
    • Lower-limb edema
    • Supraclavicular or other lymphadenopathy
Bladder Cancer Overview
Male Infertility Overview

History Taking

-Ask about:

  • Visible or microscopic hematuria
  • Whether hematuria is painful or painless
  • Dysuria, frequency, and urgency
  • Flank or pelvic pain
  • Smoking history
  • Occupational chemical exposure
  • Previous pelvic radiotherapy
  • Recurrent Urinary Tract Infection (UTI)
  • Previous bladder tumors

Physical Examination

-General Examination

  • Assess general condition and weight loss
  • Check for peripheral edema
  • Assess for lymphadenopathy when advanced disease is suspected

 

-System-Specific Examination:

  • Examine the abdomen for masses
  • Assess for suprapubic tenderness or a palpable bladder
  • Perform a focused pelvic examination when clinically indicated

Investigations

Biochemistry / Specific Tests

  • Urinalysis

  • Urine culture when infection is suspected

  • Renal function assessment

  • Urine cytology in selected patients, particularly when high-grade disease is suspected

 

-Imaging

Computed Tomography Urography (CT Urography)

Used to assess the urinary tract and identify:

  • Bladder masses

  • Upper urinary tract lesions

  • Hydronephrosis

  • Regional or distant disease

 

-Special / Confirmatory Tests

Cystoscopy

Direct visualization of the bladder and detection of suspicious lesions.

 

Transurethral Resection of Bladder Tumor (TURBT)

Provides tissue for histological diagnosis and determines tumor stage and grade.

 

-Important Investigation Note

Cystoscopy with TURBT is central to the diagnosis and initial management of suspected Bladder Cancer.

Diagnosis

-Bladder Cancer is diagnosed by:

Hematuria or suspicious urinary symptoms → cystoscopy → identification of bladder lesion → TURBT and histological examination → tumor staging and grading.

Imaging is used to assess the upper urinary tract and stage more advanced disease.

Home / Home / Clinical Cases / Urology System Clinical Cases / Bladder Cancer
Related Topics

Management

Bladder Cancer · Management Overview

Stage-Based Management at a Glance
Ta / T1 / CIS
Non-muscle invasive (NMIBC)
TURBT → intravesical therapy (BCG or chemotherapy). Surveillance cystoscopy. Avoid cystectomy unless high-risk recurrence.
T2
Muscle invasive (MIBC)
Neoadjuvant cisplatin-based chemo → radical cystectomy. Bladder-sparing (TMT) in selected patients.
T3 / T4a
Locally advanced
Neoadjuvant chemo → radical cystectomy + pelvic lymph node dissection. Adjuvant nivolumab if pT3+.
T4b / M1
Metastatic
Cisplatin-based chemo (GC / MVAC) → maintenance avelumab. PD-L1+: pembrolizumab. FGFR3 mut: erdafitinib.
Intravesical & Systemic Therapy
Intravesical — NMIBC
BCG — gold standard for high-risk NMIBC; 6-week induction + maintenance
Mitomycin C — intermediate risk; single instillation post-TURBT
Gemcitabine + docetaxel — BCG-unresponsive NMIBC
Neoadjuvant — MIBC
GC (gemcitabine + cisplatin) — standard; ↑ OS vs surgery alone
ddMVAC — dose-dense MVAC; alternative if GC not tolerated
Carboplatin-based if cisplatin-ineligible (eGFR <60, poor PS)
Advanced / Metastatic
Maintenance avelumab — after stable/response on 1st-line chemo
Pembrolizumab — 2nd line or cisplatin-ineligible PD-L1+
Erdafitinib — FGFR2/3 mutation; 2nd line

Bladder Cancer · Surgical Management

Surgical Options
TURBT
  • Transurethral resection of bladder tumour
  • 1st-line for all stages — diagnostic + therapeutic
  • Re-TURBT at 4–6 weeks if T1 or incomplete resection
  • Photodynamic / NBI guidance improves detection
Radical Cystectomy
  • Standard of care for MIBC (T2–T4a)
  • Removes bladder + prostate/uterus/anterior vaginal wall
  • Bilateral pelvic lymph node dissection mandatory
  • Open, laparoscopic, or robotic (RARC) approaches
Trimodal Therapy (TMT)
  • Bladder-sparing alternative to cystectomy
  • Maximal TURBT → concurrent chemoradiation
  • Cisplatin or 5-FU/MMC as radiosensitiser
  • Salvage cystectomy if residual/recurrent MIBC
Partial Cystectomy
  • Rare — only solitary tumour at dome/wall, away from trigone
  • Adequate surgical margins required
  • High local recurrence risk — use selectively
Surveillance Post-TURBT
  • Low risk: cystoscopy at 3 months → then annually × 5 yrs
  • High risk: every 3 months × 2 yrs → every 6 months × 3 yrs
  • Urine cytology at each visit
Pelvic Lymph Node Dissection
  • Performed with radical cystectomy
  • Extended template preferred — ↑ staging accuracy + OS
  • Removes: obturator, external/internal iliac, presacral nodes

Bladder Cancer · Urinary Diversion After Cystectomy

Types of Urinary Diversion
Ileal Conduit
Incontinent — most common
  • Ureters → isolated ileal segment → stoma (right lower abdomen)
  • Urine drains continuously into external bag
  • Simplest, shortest operative time — preferred in elderly/comorbid
  • No need for catheterisation
Orthotopic Neobladder
Continent — urethra-connected
  • Ileum fashioned into reservoir → anastomosed to urethra
  • Patient voids normally — no stoma, no bag
  • Requires intact urethra + sphincter; not for urethral involvement
  • Risk: nocturnal incontinence, urinary retention (self-catheterise)
Continent Cutaneous Reservoir
Continent — catheterisable stoma
  • Pouch constructed from bowel → continent stoma on abdomen
  • Patient self-catheterises 4–6× daily — no external bag
  • Indiana pouch / Kock pouch most common types
  • Used when urethra cannot be preserved
Choosing the right diversion:   Ileal conduit — elderly, comorbid, short operative time needed   Neobladder — young, fit, intact urethra, motivated patient   Continent reservoir — urethra compromised but patient wants no external bag
Key Complications of Urinary Diversion
Early
Urine leak — anastomotic leak; managed with stenting or reoperation
Ileus — bowel dysfunction post-bowel resection
Infection / pyelonephritis — ascending UTI
Late
Ureteroileal stricture → hydronephrosis → renal impairment
Metabolic acidosis — hyperchloraemic; bowel reabsorbs urinary chloride
Vitamin B12 deficiency — ileal resection impairs absorption

Complications

  • Recurrent tumor
  • Progression to muscle-invasive disease
  • Metastatic disease
  • Ureteric obstruction
  • Hydronephrosis
  • Kidney dysfunction
  • Severe hematuria
  • Anemia
  • Urinary obstruction

Prognosis

The prognosis of Bladder Cancer depends mainly on tumor stage, grade, presence of carcinoma in situ, recurrence, progression, and metastatic spread. Non-muscle-invasive disease generally has a better prognosis but often recurs, while muscle-invasive and metastatic disease carry a significantly worse prognosis

Key Points / Clinical Pearls

  • Bladder Cancer is most commonly urothelial carcinoma.
  • Painless visible hematuria is the classic presentation.
  • Smoking is the most important modifiable risk factor.
  • Occupational chemical exposure can increase risk.
  • Hematuria may be intermittent.
  • Cystoscopy is central to diagnosis.
  • TURBT provides histological diagnosis and initial staging.
  • NMIBC is confined to the mucosa or lamina propria.
  • MIBC invades the detrusor muscle.
  • Intravesical BCG is used for appropriate high-risk NMIBC.
  • Radical cystectomy is a major treatment for MIBC.
  • Bladder-preserving multimodal treatment is possible in selected patients.
  • Bladder Cancer has a high recurrence rate.